Cargando…

The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis

AIM: This study investigated whether or not the hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC‐GRIm‐Score) serves as a prognostic indicator for HCC patients treated with atezolizumab and bevacizumab (Atez/Bev). METHODS: A total of 405 HCC patients who received Atez/Bev from Septe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatanaka, Takeshi, Naganuma, Atsushi, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Kakizaki, Satoru, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Kumada, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972107/
https://www.ncbi.nlm.nih.gov/pubmed/36156452
http://dx.doi.org/10.1002/cam4.5294
_version_ 1784898252185796608
author Hatanaka, Takeshi
Naganuma, Atsushi
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Shimada, Noritomo
Kawata, Kazuhito
Kosaka, Hisashi
Kakizaki, Satoru
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Kaibori, Masaki
Iijima, Hiroko
Hiasa, Yoichi
Kumada, Takashi
author_facet Hatanaka, Takeshi
Naganuma, Atsushi
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Shimada, Noritomo
Kawata, Kazuhito
Kosaka, Hisashi
Kakizaki, Satoru
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Kaibori, Masaki
Iijima, Hiroko
Hiasa, Yoichi
Kumada, Takashi
author_sort Hatanaka, Takeshi
collection PubMed
description AIM: This study investigated whether or not the hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC‐GRIm‐Score) serves as a prognostic indicator for HCC patients treated with atezolizumab and bevacizumab (Atez/Bev). METHODS: A total of 405 HCC patients who received Atez/Bev from September 2020 to January 2022 at 22 different institutions were included in this retrospective study. The HCC‐GRIm score was based on the combination of the albumin level (<3.5 g/L = 1 point), lactate dehydrogenase (≥245 U/L = 1 point), neutrophil‐to‐lymphocyte ratio (≥4.8 = 1 point), aspartate aminotransferase‐to‐alanine aminotransferase ratio (≥1.44 = 1 point), and total bilirubin level (≥1.3 mg/dl = 1 point). Patients were divided into the low‐score group (0, 1, or 2 points) and the high‐score group (3, 4, or 5 points). RESULTS: There were 89 (22.0%), 141 (34.8%), 106 (26.2%), 49 (12.1%), 16 (4.0%), and 4 (1.0%) patients with scores of 0, 1, 2, 3, 4, 5, respectively. The progression‐free survival (PFS) in the low‐score group was significantly longer than that in the high‐score group (median 7.8 vs. 3.5 months, p < 0.001). The median overall survival (OS) of the low‐score group was not reached at the time cutoff, with a 1‐year survival rate of 75.5%, whereas the median OS of the high‐score group was 8.5 months, showing a significant difference (p < 0.001). A high HCC‐GRIm score was a significant unfavorable factor associated with the PFS and OS in multivariate analyses (p = 0.002 and p < 0.001, respectively). CONCLUSIONS: The HCC‐GRIm score serves as a novel prognostic score for HCC patients treated with Atez/Bev.
format Online
Article
Text
id pubmed-9972107
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99721072023-03-01 The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis Hatanaka, Takeshi Naganuma, Atsushi Hiraoka, Atsushi Tada, Toshifumi Hirooka, Masashi Kariyama, Kazuya Tani, Joji Atsukawa, Masanori Takaguchi, Koichi Itobayashi, Ei Fukunishi, Shinya Tsuji, Kunihiko Ishikawa, Toru Tajiri, Kazuto Ochi, Hironori Yasuda, Satoshi Toyoda, Hidenori Ogawa, Chikara Nishimura, Takashi Shimada, Noritomo Kawata, Kazuhito Kosaka, Hisashi Kakizaki, Satoru Tanaka, Takaaki Ohama, Hideko Nouso, Kazuhiro Morishita, Asahiro Tsutsui, Akemi Nagano, Takuya Itokawa, Norio Okubo, Tomomi Arai, Taeang Imai, Michitaka Koizumi, Yohei Nakamura, Shinichiro Kaibori, Masaki Iijima, Hiroko Hiasa, Yoichi Kumada, Takashi Cancer Med RESEARCH ARTICLES AIM: This study investigated whether or not the hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC‐GRIm‐Score) serves as a prognostic indicator for HCC patients treated with atezolizumab and bevacizumab (Atez/Bev). METHODS: A total of 405 HCC patients who received Atez/Bev from September 2020 to January 2022 at 22 different institutions were included in this retrospective study. The HCC‐GRIm score was based on the combination of the albumin level (<3.5 g/L = 1 point), lactate dehydrogenase (≥245 U/L = 1 point), neutrophil‐to‐lymphocyte ratio (≥4.8 = 1 point), aspartate aminotransferase‐to‐alanine aminotransferase ratio (≥1.44 = 1 point), and total bilirubin level (≥1.3 mg/dl = 1 point). Patients were divided into the low‐score group (0, 1, or 2 points) and the high‐score group (3, 4, or 5 points). RESULTS: There were 89 (22.0%), 141 (34.8%), 106 (26.2%), 49 (12.1%), 16 (4.0%), and 4 (1.0%) patients with scores of 0, 1, 2, 3, 4, 5, respectively. The progression‐free survival (PFS) in the low‐score group was significantly longer than that in the high‐score group (median 7.8 vs. 3.5 months, p < 0.001). The median overall survival (OS) of the low‐score group was not reached at the time cutoff, with a 1‐year survival rate of 75.5%, whereas the median OS of the high‐score group was 8.5 months, showing a significant difference (p < 0.001). A high HCC‐GRIm score was a significant unfavorable factor associated with the PFS and OS in multivariate analyses (p = 0.002 and p < 0.001, respectively). CONCLUSIONS: The HCC‐GRIm score serves as a novel prognostic score for HCC patients treated with Atez/Bev. John Wiley and Sons Inc. 2022-09-26 /pmc/articles/PMC9972107/ /pubmed/36156452 http://dx.doi.org/10.1002/cam4.5294 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Hatanaka, Takeshi
Naganuma, Atsushi
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Shimada, Noritomo
Kawata, Kazuhito
Kosaka, Hisashi
Kakizaki, Satoru
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Koizumi, Yohei
Nakamura, Shinichiro
Kaibori, Masaki
Iijima, Hiroko
Hiasa, Yoichi
Kumada, Takashi
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
title The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
title_full The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
title_fullStr The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
title_full_unstemmed The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
title_short The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
title_sort hepatocellular carcinoma modified gustave roussy immune score (hcc‐grim score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: a multicenter retrospective analysis
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972107/
https://www.ncbi.nlm.nih.gov/pubmed/36156452
http://dx.doi.org/10.1002/cam4.5294
work_keys_str_mv AT hatanakatakeshi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT naganumaatsushi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT hiraokaatsushi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tadatoshifumi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT hirookamasashi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kariyamakazuya thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tanijoji thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT atsukawamasanori thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT takaguchikoichi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT itobayashiei thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT fukunishishinya thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tsujikunihiko thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT ishikawatoru thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tajirikazuto thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT ochihironori thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT yasudasatoshi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT toyodahidenori thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT ogawachikara thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT nishimuratakashi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT shimadanoritomo thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kawatakazuhito thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kosakahisashi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kakizakisatoru thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tanakatakaaki thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT ohamahideko thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT nousokazuhiro thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT morishitaasahiro thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tsutsuiakemi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT naganotakuya thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT itokawanorio thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT okubotomomi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT araitaeang thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT imaimichitaka thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT koizumiyohei thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT nakamurashinichiro thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kaiborimasaki thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT iijimahiroko thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT hiasayoichi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kumadatakashi thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT thehepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT hatanakatakeshi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT naganumaatsushi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT hiraokaatsushi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tadatoshifumi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT hirookamasashi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kariyamakazuya hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tanijoji hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT atsukawamasanori hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT takaguchikoichi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT itobayashiei hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT fukunishishinya hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tsujikunihiko hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT ishikawatoru hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tajirikazuto hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT ochihironori hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT yasudasatoshi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT toyodahidenori hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT ogawachikara hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT nishimuratakashi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT shimadanoritomo hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kawatakazuhito hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kosakahisashi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kakizakisatoru hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tanakatakaaki hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT ohamahideko hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT nousokazuhiro hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT morishitaasahiro hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT tsutsuiakemi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT naganotakuya hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT itokawanorio hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT okubotomomi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT araitaeang hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT imaimichitaka hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT koizumiyohei hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT nakamurashinichiro hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kaiborimasaki hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT iijimahiroko hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT hiasayoichi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT kumadatakashi hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis
AT hepatocellularcarcinomamodifiedgustaveroussyimmunescorehccgrimscoreasanovelprognosticscoreforpatientstreatedwithatezolizumabandbevacizumabamulticenterretrospectiveanalysis